All In Biotech

Drug Trial Radar · NCT01126437

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)

Last checked: Nov 20, 2026Latest source record: Jun 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 17,183 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

17,183

Actual

Start

May 2010

Primary completion

May 2013

Study completion May 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 19, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies. Therefore, prospective data from a trial of adequate size and duration is required to establish that compared to tiotropium HandiHaler®, tiotropium Respimat® will have (a) similar effects on safety and (b) similar or superior effects on exacerbations.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • tiotropium 18 mcgDrug

    HandiHaler

  • tiotropium 1.25 mcg (2 actuations/day)Drug

    soft mist inhaler 2 actuations=2 puffs/day

  • tiotropium 2.5 mcg (2 actuations/day)Drug

    soft mist inhaler (2 actuations=2 puffs/day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to All-Cause MortalityTime frame: Up to 3 years
  2. Time to First COPD ExacerbationTime frame: Up to 3 years

Locations

1,191 sites in 51 countries. Site status is shown where the registry gives one.

  • 205.452.01107 Boehringer Ingelheim Investigational Site

    Athens, Alabama

  • 205.452.01023 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 205.452.01035 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 205.452.01052 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 205.452.01219 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 205.452.01227 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 205.452.01280 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 205.452.01198 Boehringer Ingelheim Investigational Site

    Florence, Alabama

  • 205.452.01244 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 205.452.01041 Boehringer Ingelheim Investigational Site

    Montgomery, Alabama

  • 205.452.01070 Boehringer Ingelheim Investigational Site

    Anchorage, Alaska

  • 205.452.01218 Boehringer Ingelheim Investigational Site

    Chandler, Arizona

  • 205.452.01175 Boehringer Ingelheim Investigational Site

    Mesa, Arizona

  • 205.452.01200 Boehringer Ingelheim Investigational Site

    Mesa, Arizona

  • 205.452.01317 Boehringer Ingelheim Investigational Site

    Mesa, Arizona

  • 205.452.01350 Boehringer Ingelheim Investigational Site

    Pheonix, Arizona

  • 205.452.01254 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 205.452.01283 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 205.452.01315 Boehringer Ingelheim Investigational Site

    Tempe, Arizona

  • 205.452.01158 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 205.452.01161 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 205.452.01302 Boehringer Ingelheim Investigational Site

    Anaheim, California

  • 205.452.01038 Boehringer Ingelheim Investigational Site

    Encinitas, California

  • 205.452.01313 Boehringer Ingelheim Investigational Site

    Fountain Valley, California

  • 205.452.01375 Boehringer Ingelheim Investigational Site

    Fountain Valley, California

  • 205.452.01074 Boehringer Ingelheim Investigational Site

    Fullerton, California

  • 205.452.01345 Boehringer Ingelheim Investigational Site

    Lancaster, California

  • 205.452.01171 Boehringer Ingelheim Investigational Site

    Lincoln, California

  • 205.452.01339 Boehringer Ingelheim Investigational Site

    Lomita, California

  • 205.452.01298 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 205.452.01356 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 205.452.01148 Boehringer Ingelheim Investigational Site

    Orange, California

  • 205.452.01111 Boehringer Ingelheim Investigational Site

    Palm Springs, California

  • 205.452.01147 Boehringer Ingelheim Investigational Site

    Paramount, California

  • 205.452.01071 Boehringer Ingelheim Investigational Site

    Poway, California

  • 205.452.01089 Boehringer Ingelheim Investigational Site

    Rancho Cucamonga, California

  • 205.452.01097 Boehringer Ingelheim Investigational Site

    Redlands, California

  • 205.452.01078 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 205.452.01176 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 205.452.01346 Boehringer Ingelheim Investigational Site

    San Diego, California

Showing 40 of 1,191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.